Nov 4, 4:08 PM ET
Arcus Biosciences reported third-quarter 2026 results on November 4, 2026. Quarterly revenue fell to $9 million from $26 million, while the net loss narrowed to $128 million from $135 million, and the company said cash runway extends into 2029 after an October equity financing.
- Q3 2026 net loss was $128 million, or $1.00 per share, versus $135 million, or $1.27 per share, in Q3 2025.
- Q3 2026 revenue was $9 million versus $26 million a year earlier; the company expects full-year 2026 GAAP revenue of $70 million to $75 million.
- Cash, cash equivalents and marketable securities were $694 million at September 30, 2026, plus $288 million gross proceeds from an October equity financing.
- Enrollment in the PEAK-1 Phase 3 study is expected to complete in the next two to three months; PEAK-20 is expected to begin in the fourth quarter of 2026.
Read the filing on SEC.gov ↗
Oct 23, 4:12 PM ET
Arcus Biosciences sold 16,428,572 shares of common stock at a public offering price of $17.50 per share, including the full exercise of the underwriters' option, and the offering closed on October 23, 2026. The company received net proceeds of approximately $269.7 million after underwriting discounts, commissions and estimated offering expenses. Shareholders face a larger share count, and the filing does not describe how the proceeds will be used.
- Public offering price of $17.50 per share; underwriters agreed to buy the shares from the company at $16.45 per share.
- Total of 16,428,572 shares issued, including 2,142,857 shares from the underwriters' option exercised in full.
- Offering closed October 23, 2026, with net proceeds of approximately $269.7 million.
- Underwriters were Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC, under Form S-3 Registration No. 333-293750.
Read the filing on SEC.gov ↗
Oct 21, 4:09 PM ET
Arcus Biosciences disclosed a preliminary estimate of about $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026. The figure is unaudited, subject to financial closing procedures, and Ernst & Young has not reviewed it, so it may change. The filing contains no revenue, profit or guidance figures, so it gives shareholders a liquidity snapshot rather than full results.
- Preliminary cash, cash equivalents and marketable securities: approximately $694.0 million as of September 30, 2026
- Figure is unaudited and subject to completion of financial closing procedures and management review
- Ernst & Young LLP has not audited or reviewed the preliminary data
- Filing does not include revenue, net income, EPS or guidance
Read the filing on SEC.gov ↗
Oct 20, 8:33 AM ET
Arcus Biosciences presented new data from its ARC-20 platform study of casdatifan, alone or in combination, for clear cell renal cell carcinoma, using a data cutoff of September 4, 2026. The filing reports response, progression and survival figures across first-line, second-line and late-line cohorts, with no unexpected safety signals cited for each regimen.
- Second-line casdatifan plus cabozantinib (n=43): median PFS 14.5 months, 18-month landmark overall survival 77%, cORR 44%
- First-line casdatifan plus zimberelimab (n=30): cORR 50%, landmark PFS 69% at 12 months, primary progression 6.7%
- Late-line casdatifan monotherapy (n=121): median overall survival 35 months, median PFS 13 months, cORR 36%
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.